Joyce M Teng, MD
Dermatology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations · Lpch Medical Group Div of Lucile · Stanford Health Care
Looking this up.
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Teng’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C55362 · Current
Licensed to practise in California · since 2012 · expires 2028-07-31 · Vanderbilt University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$4,475
Medicare paid this office $4,475 for 20 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
20 Original Medicare patients in 2024. Average age 66 · 85 and older 0% · Health risk score 1.65. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65%.
The office billed $18,609, Medicare allowed $6,063 and paid $4,475; for 34 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$30,720 in 2024
Medicaid paid $30,720 for 271 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 257 | $28,959 |
| New patient visit (30+ min) | 14 | $1,761 |
| 2024 | 271 | 2 | 31 | $30,720 |
| 2023 | 348 | 2 | 36 | $29,241 |
| 2022 | 487 | 4 | 34 | $39,424 |
| 2021 | 658 | 3 | 44 | $51,251 |
| 2020 | 678 | 3 | 46 | $50,481 |
| 2019 | 874 | 5 | 46 | $67,034 |
| 2018 | 727 | 5 | 45 | $54,358 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 286 | $25,490 |
| Short return visit (20+ min) | 62 | $3,750 |
2022
| Return visit (30+ min) | 251 | $20,967 |
| Short return visit (20+ min) | 144 | $8,928 |
| New patient visit (30+ min) | 79 | $7,649 |
| New patient visit (45+ min) | 13 | $1,880 |
2021
| Return visit (30+ min) | 244 | $21,581 |
| New patient visit (30+ min) | 161 | $15,808 |
| Short return visit (20+ min) | 253 | $13,862 |
2020
| Return visit (30+ min) | 430 | $33,457 |
| New patient visit (30+ min) | 114 | $10,701 |
| Short return visit (20+ min) | 134 | $6,322 |
2019
| Return visit (30+ min) | 471 | $35,876 |
| New patient visit (30+ min) | 131 | $13,349 |
| Short return visit (20+ min) | 226 | $10,963 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 30 | $5,471 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 16 | $1,375 |
2018
| Return visit (30+ min) | 375 | $27,686 |
| Short return visit (20+ min) | 209 | $10,162 |
| New patient visit (30+ min) | 89 | $8,865 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 41 | $6,542 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 13 | $1,103 |
Drugs they prescribed that Part D paid
$31,609
Pharmacies billed $31,609 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 50) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
50 generic and 0 brand-name prescriptions · $31,609 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sirolimus | 31 | $30,653 | $989 |
Year by year
| 2024 | 50 | None | 0% (0) | 0% | $31,609 |
| 2023 | 31 | None | 0% (0) | None | $16,739 |
| 2022 | 46 | None | 0% (0) | None | $23,325 |
| 2021 | 41 | None | 0% (0) | None | $26,243 |
| 2020 | 31 | None | 0% (0) | None | $30,364 |
| 2019 | 26 | None | 0% (0) | None | $12,212 |
| 2017 | 11 | None | 0% (0) | None | $817 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Sirolimus | 20 | $15,381 | $769 |
2022: 1 drug
| Sirolimus | 30 | $21,764 | $725 |
2021: 1 drug
| Sirolimus | 27 | $24,637 | $912 |
2020: 1 drug
| Sirolimus | 25 | $29,914 | $1,197 |
2019: 1 drug
| Sirolimus | 14 | $11,140 | $796 |
Money from drug and device companies
$43,354 in 2025
| 2025 | 7 | 44 | $40,013 | $43,354 |
| 2024 | 9 | 20 | $26,850 | $30,899 |
| 2023 | 5 | 11 | $9,120 | $9,442 |
| 2022 | 5 | 10 | $13,180 | $13,644 |
| 2021 | 3 | 5 | $14,620 | $14,620 |
| 2020 | 5 | 6 | $10,395 | $10,401 |
| 2019 | 5 | 13 | $3,220 | $4,892 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Chiesi USA | Filsuvez | $15,167 | 12 payments
|
| Pfizer | Litfulo | $10,149 | 8 payments
|
| Abeona Therapeutics | Zevaskyn | $7,151 | 6 payments
|
| BioCryst Pharmaceuticals | None | $3,834 | 2 payments
|
| Novartis Pharmaceuticals | Vijoice | $3,818 | 11 payments
|
| Incyte | None | $3,180 | 2 payments
|
See all 44 published payments
| Novartis Pharmaceuticals | Consulting · 2025-12-11 | Vijoice | $900 |
| Novartis Pharmaceuticals | Meals · 2025-12-02 | Vijoice | $29 |
| Chiesi USA | Consulting · 2025-11-25 | Filsuvez | $3,640 |
| Novartis Pharmaceuticals | Travel · 2025-11-14 | Vijoice | $210 |
| Novartis Pharmaceuticals | Meals · 2025-11-14 | Vijoice | $225 |
| Novartis Pharmaceuticals | Travel · 2025-11-14 | Vijoice | $24 |
| Novartis Pharmaceuticals | Travel · 2025-11-14 | Vijoice | $333 |
| Novartis Pharmaceuticals | Travel · 2025-11-14 | Vijoice | $152 |
| Chiesi USA | Meals · 2025-10-17 | Filsuvez | $31 |
| Chiesi USA | Meals · 2025-10-10 | Filsuvez | $162 |
| Pfizer | Consulting · 2025-09-25 | None | $1,863 |
| Pfizer | Consulting · 2025-09-11 | Litfulo | $745 |
| Pfizer | Consulting · 2025-09-10 | None | $1,863 |
| Abeona Therapeutics | Honoraria · 2025-08-12 | Zevaskyn | $2,975 |
| Abeona Therapeutics | Meals · 2025-08-05 | Zevaskyn | $99 |
| Incyte | Consulting · 2025-08-04 | None | $3,000 |
| Novartis Pharmaceuticals | Consulting · 2025-07-29 | Vijoice | $1,800 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Vijoice | $112 |
| Pfizer | Meals · 2025-07-25 | Litfulo | $92 |
| Abeona Therapeutics | Meals · 2025-07-23 | Zevaskyn | $50 |
| Incyte | Meals · 2025-07-10 | None | $180 |
| BioCryst Pharmaceuticals | Consulting · 2025-06-25 | None | $1,046 |
| Krystal Biotech | Meals · 2025-06-20 | Vyjuvek | $19 |
| Chiesi USA | Travel · 2025-05-29 | Filsuvez | $402 |
| Chiesi USA | Paid to speak or teach · 2025-05-29 | Filsuvez | $9,982 |
| Krystal Biotech | Meals · 2025-05-16 | Vyjuvek | $17 |
| Abeona Therapeutics | Honoraria · 2025-05-08 | Zevaskyn | $3,825 |
| Abeona Therapeutics | Meals · 2025-05-08 | Zevaskyn | $50 |
| Pfizer | Consulting · 2025-05-02 | None | $1,863 |
| Chiesi USA | Meals · 2025-05-02 | Filsuvez | $51 |
| Chiesi USA | Travel · 2025-04-18 | Filsuvez | $122 |
| Chiesi USA | Meals · 2025-04-18 | Filsuvez | $21 |
| Chiesi USA | Meals · 2025-04-18 | Filsuvez | $45 |
| Chiesi USA | Meals · 2025-04-17 | Filsuvez | $105 |
| Chiesi USA | Travel · 2025-04-17 | Filsuvez | $259 |
| Chiesi USA | Travel · 2025-04-17 | Filsuvez | $348 |
| Pfizer | Consulting · 2025-03-31 | None | $1,490 |
| Pfizer | Consulting · 2025-03-26 | Litfulo | $745 |
| Krystal Biotech | Meals · 2025-03-21 | Vyjuvek | $18 |
| Pfizer | Consulting · 2025-03-20 | None | $1,490 |
| Abeona Therapeutics | Meals · 2025-03-09 | Zevaskyn | $152 |
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Vijoice | $28 |
| Novartis Pharmaceuticals | Meals · 2025-02-05 | Vijoice | $5 |
| BioCryst Pharmaceuticals | Consulting · 2025-02-05 | None | $2,788 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $30,899
| Mitsubishi Tanabe Pharma America | None | $8,750 | 3 payments
|
| Novartis Pharmaceuticals | Vijoice | $4,012 | 4 payments
|
| Novartis Pharma AG | Piqray | $4,000 | 1 payment
|
| Pierre Fabre Pharmaceuticals | Hemangeol | $3,634 | 5 payments
|
| Chiesi USA | Filsuvez | $3,565 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $3,080 | 1 payment
|
| LEO Pharma | None | $3,057 | 3 payments
|
| BioCryst Pharmaceuticals | None | $697 | 1 payment
|
| Pfizer | Litfulo | $103 | 1 payment
|
2023: $9,442
| Nobelpharma America | Hyftor | $4,562 | 5 payments
|
| Novartis Pharmaceuticals | Vijoice | $4,038 | 3 payments
|
| Mitsubishi Tanabe Pharma America | None | $720 | 1 payment
|
| Amryt Pharma Holdings | None | $107 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $13,644
| Amryt Pharma Holdings | None | $8,878 | 4 payments
|
| Novartis Pharmaceuticals | Vijoice | $2,445 | 2 payments
|
| Pierre Fabre Pharmaceuticals | Hemangeol | $2,115 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $134 | 1 payment
|
| Pfizer | Cibinqo | $72 | 1 payment
|
2021: $14,620
| Amryt Pharma Holdings | None | $7,930 | 2 payments
|
| Novartis Pharmaceuticals | None | $5,040 | 2 payments
|
| BioCryst Pharmaceuticals | Orladeyo | $1,650 | 1 payment
|
2020: $10,401
| Pfizer | Eucrisa | $4,406 | 2 payments
|
| Regeneron Pharmaceuticals | Dupixent | $3,720 | 1 payment
|
| Mitsubishi Tanabe Pharma Holdings America | None | $1,240 | 1 payment
|
| Ipsen Biopharmaceuticals | None | $805 | 1 payment
|
| LEO Pharma AS | None | $230 | 1 payment
|
2019: $4,892
| LEO Pharma AS | Enstilar | $4,442 | 8 payments
|
| Solta Medical a division of Bausch Health US | None | $207 | 2 payments
|
| Pierre Fabre Pharmaceuticals | None | $145 | 1 payment
|
| LEO Pharma | Enstilar | $64 | 1 payment
|
| Celgene | Otezla | $33 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Epik-L1: A Phase II/III Double-Blind, Randomized, Placebo-Controlled Study To Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With Pik3ca Mutations, Preceded By An Explo · 2025 | Their institution | $2,815,873 |
| Novartis Pharmaceuticals Corporation · Epik-L1: A Phase II/III Double-Blind, Randomized, Placebo-Controlled Study To Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With Pik3ca Mutations, Preceded By An Exploratory Stage To Assess the Dose and Early Efficacy Signal of Alpelisib in These Patients · 2024 | Their institution | $2,270,780 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2022 | Their institution | $908,408 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2021 | Their institution | $750,486 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2023 | Their institution | $665,754 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2024 | Their institution | $503,725 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2025 | Their institution | $295,613 |
| Amgen Inc. · Ppso-004/20200057 (Sprout Rollover) · 2021 | Their institution | $218,337 |
| Amgen Inc. · Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate To Severe Plaque Pso (Ppso-003) · 2020 | Their institution | $151,554 |
| Amgen Inc. · Ppso-003/20200056 (Sprout) · 2021 | Their institution | $139,134 |
| Amgen Inc. · Ph3b Otezla in Peds Mod/Sev Pso Sprout Rollover · 2024 | Their institution | $133,875 |
| Amgen Inc. · Ph3b Otezla in Peds Mod/Sev Pso (Sprout Rollover) · 2023 | Their institution | $116,280 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Arq-151 Cream 0.05% Administered Qd in Subjects With Atopic Dermatitis · 2023 | Their institution | $79,488 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.15% and Arq-151 Cream 0.05% in Subjects With Atopic Dermatitis · 2024 | Their institution | $64,971 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.15% and Arq-151 Cream 0.05% in Subjects With Atopic Dermatitis · 2023 | Their institution | $55,749 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2023 | Their institution | $54,052 |
| Amgen Inc. · Ph3 Otezla in Peds Mod/Sev Pso (Sprout) · 2022 | Their institution | $51,039 |
| Amgen Inc. · A Phase 3b, Multi Center, Open-Label, Long-Term Extension Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Psoriasis · 2025 | Their institution | $48,670 |
| LEO Pharma AS · Tralokinumab Confirmatory Trial in Adolescents · 2019 | Their institution | $41,338 |
| Amgen Inc. · Ph3b Otezla in Peds Mod/Sev Pso (Sprout Rollover) · 2022 | Their institution | $40,255 |
| LEO Pharma AS · Tralokinumab: Confirmatory Trial in Adolescents · 2020 | Their institution | $32,301 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months To <6 Years With Severe Atopic Dermatitis · 2021 | Their institution | $27,948 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2020 | Their institution | $27,623 |
| LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2020 | Their institution | $26,643 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months To 18 Years of Age With Atopic Dermatitis · 2019 | Their institution | $26,578 |
| PFIZER INC. · A Phase 2a Randomized Doubleblind Placebo Controlled Study Investigating the Safety of Ritlecitinib Pf06651600 in Adult Participants With Alopecia Areata · 2021 | Their institution | $26,340 |
| Incyte Corporation · A Study To Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo · 2025 | Their institution | $22,748 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2021 | Their institution | $22,446 |
| PFIZER INC. · A Randomized Doubleblind Placebocontrolled Study To Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019 | Their institution | $20,238 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2022 | Their institution | $19,533 |
| LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2021 | Their institution | $18,736 |
| Abeona Therapeutics, Inc. · Pz-Cel-Ry-401 · 2025 | Their institution | $18,344 |
| PFIZER INC. · An Openlabel Extension Study To Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019 | Their institution | $17,048 |
| Eli Lilly and Company · Multicenter, Double-Blind, Randomized, Placebo Controlled Study To Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 To Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis · 2019 | Their institution | $16,400 |
| LEO Pharma AS · Tralokinumab: Confirmatory Trial in Adolescents · 2021 | Their institution | $15,895 |
| Novartis Pharmaceuticals Corporation · Phase I Clinical Trial of Mek Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation · 2020 | Their institution | $14,973 |
| Janssen Research & Development, LLC · A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (=6 To <18 Years of Age) · 2019 | Their institution | $13,938 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2 3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months To 6 Years With Severe Atopic Dermatitis · 2019 | Their institution | $13,425 |
| Amgen Inc. · Efficacy and Safety Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Psor · 2023 | Their institution | $13,362 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2024 | Their institution | $10,792 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months To <6 Years With Moderate-To-Severe Atopic Dermatitis · 2022 | Their institution | $10,712 |
| Regeneron Pharmaceuticals, Inc. · An Open-Label Extension Study To Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months To <18 Years of Age With Atopic Dermatitis · 2025 | Their institution | $9,735 |
| Amgen Inc. · A Long-Term Extension Study of Apremilast Cc-10004 in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque · 2024 | Their institution | $8,839 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months To <6 Years With Severe Atopic Dermatitis · 2020 | Their institution | $8,536 |
| PFIZER INC. · An Openlabel Extension Study To Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis · 2020 | Their institution | $5,358 |
| Janssen Research & Development, LLC · A Study To Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants · 2023 | Their institution | $4,452 |
| PFIZER INC. · Abrocitinib Clinical Publication Program · 2021 | This clinician | $4,140 |
| Janssen Research & Development, LLC · A Study To Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants · 2022 | Their institution | $3,984 |
| Amgen Inc. · Efficacy and Safety Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Psor · 2022 | Their institution | $3,832 |
| Amgen Inc. · A Long-Term Extension Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Ps · 2023 | Their institution | $3,316 |
| Amgen Inc. · Efficacy and Safety Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Psor · 2020 | Their institution | $3,099 |
| PFIZER INC. · A Phase 2a Randomized Doubleblind Placebo Controlled Study Investigating the Safety of Ritlecitinib Pf06651600 in Adult Participants With Alopecia Areata · 2020 | Their institution | $2,795 |
| Amgen Inc. · Efficacy and Safety Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Psor · 2021 | Their institution | $2,679 |
| Janssen Research & Development, LLC · A Study To Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants · 2021 | Their institution | $1,672 |
| ABBVIE INC. · A Phase 3, Open-Label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib To Dupilumab in Children From 2 To Less Than 12 Years of Age With Moderate To Severe Atopic Dermatitis · 2024 | This clinician | $1,421 |
| Janssen Research & Development, LLC · A Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants · 2020 | Their institution | $1,176 |
| Celgene Corporation · A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years With Moderate To Severe Plaque Psoriasis · 2020 | Their institution | $1,007 |
| NOBELPHARMA AMERICA, LLC · Hyftor · 2023 | Their institution | $700 |
| PFIZER INC. · Abrocitinib Clinical Publication Program · 2020 | This clinician | $330 |
| Novartis Pharmaceuticals Corporation · Epik-L1: A Phase II/III Double-Blind, Randomized, Placebo-Controlled Study To Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With Pik3ca Mutations, Preceded By An Exploratory Stage To Assess the Dose and Early Efficacy Signal of Alpelisib in These Patients · 2023 | Their institution | $284 |
| Amgen Inc. · A Long-Term Extension Study of Apremilast (Cc-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate To Severe Plaque Ps · 2022 | Their institution | $102 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1801850854
- Licence
- CA C55362, WI 48924California C55362: Current · expires 2028-07-31
- Trained
- Vanderbilt University School of Medicine, 2001
- Group
- Lpch Medical Group Div of Lucile · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207NP0225X (207NP0225X); Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St, Redwood City, CA, 94063
- NPI first listed
- 2006-04-14
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 770 Welch Rd, Palo Alto, CA, 94304